Just a few days after its editorial urging more state funding for Piedmont Triad Research Park, the Winston-Salem Journal today advocates for a “cash infusion” for another research park tenant:
Tengion is in a highly-competitive field where research requires heavy, constant cash infusions. The company acknowledged last week that its short-term fate depends on attracting a buyer or new investment by May before it runs out of money. That acknowledgment was akin to a call for help. The good news is that the call will likely be heard.
The “best, and fortunately most likely, case” is that Tengion’s research and development continues to move forward, said Michael Lord, an associate professor of management at Wake Forest University. “It’s just a matter of how much, how fast and who funds it.”
Let’s hope this company that’s important to our transforming economy gets a significant cash infusion soon.
I applaud the work that Tengion is doing in the medical field, and I hope they are successful. Still I can’t help but wonder who the Journal thinks should be the supplier of these “constant cash infusions.”
